ADVOCACY
-
2022 CHS Annual Report
Please CLICK HERE to access the 2022 CHS Annual Report. Should you want to consult the complete Financial Statements, you can do so by clicking HERE.
-
Justice Krever is no longer with us … but his legacy is very much alive
The Commission of Inquiry on the Blood System in Canada was a public investigation of the Canadian blood system, which had been contaminated with HIV...
-
Canadian standards of care for bleeding disorders: Are they met?
Following the development of the Canadian Integrated and Comprehensive Care Standards for Inherited Bleeding Disorders (Second Edition) in 2020, the Canadian Inherited Bleeding Disorder Standards...
-
Hemophilia A gene therapy approved in Europe but possibly delayed in the U.S.
Last August, the European Medicines Agency (EMA) granted conditional marketing authorization to BioMarin’s Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A...
-
Hemophilia B gene therapy approved by U.S. FDA
Montreal – November 28, 2022 – The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B on November 22. Etranacogene...